SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies | Clinical Pharmacokinetics
SAGE-217 for the Treatment of Depression | NEJM
Figure 1 from Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor ...
SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies | Clinical Pharmacokinetics
SAGE-217
Sage Therapeutics: Disappointing Phase III Results Will Be A Burden (NASDAQ: SAGE) | Seeking Alpha
SAGE-217 In Major Depressive Disorder: A Multi-Center, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial
Health-Related Quality of Life In A Phase 2, Randomized, Placebo-Controlled Trial Of The GABA R Modulator SAGE-217 in Major Depr
Revisiting SAGE, climbing up the MOUNTAIN | by Sys2Research | Medium
Zuranolone (SAGE-217)|CAS 1632051-40-1|DC Chemicals
Zuranolone - Wikipedia
Sage217;sage 217;sage-217 | C25H35N3O2 | CID 123751429 - PubChem
SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
An Update On Sage Therapeutics (NASDAQ:SAGE) | Seeking Alpha
The Psychiatric Pipeline: 10 Agents to Watch
Development of Zuranolone (SAGE 217) for PPD Will Move Forward
Biopharmaceutical Company for Brain Health Disorders - Sage Therapeutics
Trial of SAGE-217 in Patients with Major Depressive Disorder | NEJM
a SAGE-217 plasma concentration over time (SAD). Mean plasma... | Download Scientific Diagram
SAGE-217 (S-812217, SGE 797, CAS Number: 1632051-40-1) | Cayman Chemical
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
a SAGE-217 plasma concentration over time (SAD). Mean plasma... | Download Scientific Diagram
SEC Filing | Sage Therapeutics, Inc.
